In a retrospective study in the European EUROS1 cohort reported in the Journal of Clinical Oncology, Mazières found that crizotinib (Xalkori) treatment was associated with an 80% response rate in patients with stage IV lung adenocarcinoma with ROS1 rearrangement.
Study Details
The study involved 31 patients who received crizotinib therapy through individual off-label use. Patients had a median age of 50.5 years, 64.5% were women, and 67.7% were never-smokers. Patients had received zero (n = 1), one (n = 9), two (n = 5), three (n = 3), or more than three (n = 13) lines of chemotherapy before crizotinib.
Responses
Among 30 patients evaluated for response, 24 (80.0%) had objective response, including complete response in 5; 2 had stable disease (disease control rate of 86.7%); and 4 had disease progression. Median progression-free survival was 9.1 months, and 12-month progression-free survival was 44%. No unexpected adverse effects were observed.
Among 26 patients who received pemetrexed (Alimta, first or second line in 22) either alone or in combination with platinum and either before or after crizotinib, the response rate to pemetrexed therapy was 57.7%, and median progression-free survival was 7.2 months.
The investigators concluded: “Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1. Prospective clinical trials with crizotinib and other ROS1 inhibitors are ongoing or planned.”
Julien Mazières, MD, PhD, of Centre Hospitalier Universitaire Toulouse, is the corresponding author of the Journal of Clinical Oncology article.
The study was supported in part by the Cancer Pharmacology of Toulouse–Oncopole and Region (CAPTOR) academic project. For full disclosures of the study authors, visit jco.ascopubs.org.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου